|Clal Biotechnology Industries Ltd -- Israel Stock|| |
ILS 327.00 323.72 9,870%
Mr. Ofer Goldberg serves as Vice President at Clal Biotechnology Industries Ltd. since September 1, 2003. Previously, Mr. Goldberg served as Director for BioCancell Therapeutics Inc from May 17, 2007 to October 21, 2009
Age: 42 VP Since 2003
972 3 612 1616 http://www.cbi.co.il
Goldberg has a Bachelors degree in Mathematics and Physics from The Hebrew University of Jerusalem and a Masters degree in Finance and Economics from the TelAviv University.
The company has return on total asset (ROA)
of (4.67) %
which means that it has lost $4.67 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of (26.55) %
meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 77.26 M in total debt with debt to equity ratio (D/E) of 9.1 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Clal Biotechnology Industries Ltd has Current Ratio of 4.64 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.
Clal Biotechnology Industries Ltd. is a private equity and VC firm specializing in development stage, preclinical; incubation, seed, startup, early venture, emerging growth, mid venture, late venture, PIPEs, and growth capital stages of financing. Clal Biotechnology Industries Ltd (CBI) is traded on Tel Aviv Stock Exchange in Israel. It is located in Tel Aviv, and employs 14 people.